NCT06066359: Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 44 | US | Fludarabine phosphate, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Neosar®, NY-ESO-1 TCR/IL-15 NK | M.D. Anderson Cancer Center | Myeloma | 08/26 | 08/28 | | |
NCT06083883: Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 |
|
|
| Suspended | 1 | 44 | US | Fludarabine phosphate, Fludarabine, Fludara®, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide, Cytoxan®, Neosar® | M.D. Anderson Cancer Center | Synovial Sarcoma, Myxoid/Round Cell Liposarcoma | 11/26 | 11/28 | | |